Company Immunovant, Inc. Nasdaq
Equities
US45258J2015
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01/19/01 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 04/21/04 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ian Gourley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Maria Alba
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jennifer Moseley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 24/20/24 |
Jay Stout
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/23/01 |
Chief Tech/Sci/R&D Officer | 66 | 01/21/01 | |
Chau Cheng
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 18/19/18 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 18/19/18 |
Douglas Hughes
BRD | Director/Board Member | 62 | 18/19/18 |
Atul Pande
BRD | Director/Board Member | 69 | 18/19/18 |
Frank Torti
CHM | Chairman | 45 | 18/19/18 |
Eric Venker
BRD | Director/Board Member | 37 | 18/20/18 |
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01/19/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 146,053,941 | 62,422,461 ( 42.74 %) | 0 | 42.74 % |
Company contact information
![address Immunovant, Inc.](https://cdn.zonebourse.com/static/address/57878422.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+34.14% | 5.11TCr | |
-6.54% | 3.94TCr | |
+34.92% | 3.85TCr | |
+12.62% | 2.64TCr | |
-12.11% | 2.62TCr | |
-13.43% | 2.1TCr | |
+43.73% | 1.4TCr | |
+31.81% | 1.25TCr | |
-4.54% | 1.16TCr |